Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.

JAMA Neurol · 2026 · PMC12910456 · PMID 41697690

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although a numerically lower number of ublituximab-treated participants experienced CDP24 compared with teriflunomide-treated participants at the end of the DBP, this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.